Total Funding
10
Total FundingGrant raised
Growth Score
pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Equalix develops and commercializes products in regenerative medicine for dermatological, neurological, and cardiovascular applications.
Peter Lelkes: Founder
Joseph P. Connell: CEO ,President & Chairman
About the Company
Eqalix, Inc. is an emerging regenerative medicine development company with a goal of enhancing the quality of life of consumers and patients by providing novel nano-materials for the repair and regeneration of diseased, traumatized, and aging tissues. Our innovative technologies are intended to revolutionize the unmet needs in multiple commercial
and therapeutic applications in the regenerative medicine space. The global market for tissue engineering and regeneration products will grow to $89.7 billion by 2016 at a compounded annual growth rate (CAGR) of 8.4%, powered by increasing focus on stem cell research, greater usage of non-autograft products, ageing baby boomers and higher investments in R&D activity.
